Loading
Discovered the TMPRSS2-ERG fusion in prostate cancer and built one of the first clinical sequencing programmes.
Arul M. Chinnaiyan is Director of the Michigan Center for Translational Pathology, S.P. Hicks Professor of Pathology and an HHMI Investigator at the University of Michigan Rogel Cancer Center. He is a pathologist-scientist known for discovering the TMPRSS2-ERG gene fusion in prostate cancer in 2005 and for building one of the first clinical sequencing programmes, MI-ONCOSEQ. His selected papers report recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, and integrative clinical genomics of advanced prostate cancer. He continues to work on comprehensive genomic profiling, long non-coding RNA and urine-based prostate cancer diagnostics.
| Title | Journal | Year |
|---|---|---|
| Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer | Science | 2005 |
| Integrative clinical genomics of advanced prostate cancer | Cell | 2015 |
The genomic definition of advanced prostate cancer, and the evidence that made molecular testing standard in it. The 19.3 percent DNA repair figure is the direct ancestor of PROfound, TRITON3, PROpel and TALAPRO-2, and the 8 percent germline figure is why a tumour result in this disease has implications for a man's relatives.
The explanation for why prostate cancer has so few targeted drugs outside the hormone axis and the DNA-repair genes: it is a quiet genome with structural rather than point-mutational damage, and the recurrent changes sit in the machinery that reads DNA rather than in kinases.
The most common single molecular event in prostate cancer, present in roughly half of tumours in most series, and the reason prostate cancer is classified by fusion status. It is also a standing reminder that finding the driver and drugging it are different problems: no ETS-directed therapy has reached the clinic.
Shares University of Michigan Rogel Cancer Center, Prostate cancer.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Gene fusion, RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Gene fusion, RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, The mutational landscape of lethal castration-resistant prostate cancer, Gene fusion, Comprehensive genomic profiling.
Shares Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, The mutational landscape of lethal castration-resistant prostate cancer, Prostate cancer.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.